Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s):  FENC

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.


TSX:FRX - Post by User

Comment by Brinkleyon Mar 10, 2013 9:34am
142 Views
Post# 21106723

RE: RE: RE: RE: Warrents

RE: RE: RE: RE: Warrents

I found some information from the 2011 annual report.  

 

there were 2 events

1) Southpointe capital bought 240 million shares pre consolidation for 3cents and were given a warrent with each share to buy a share at 8 cents any time before April 2015

2) in Feb 2011 shareholders were given the same opportunity and 84.5 million shares were sold at .03 and they were given a right to buy a share at 8 cents by Feb 2016

 

the post consolidation price was $.54/share for the stock and $1.44 for the warrent.

 

There are 18 million warrents out right now.  If the shareprice gets over $1.44 and these warrents get issued the company would get $26 million

 

I was very surprised to see that the stock price today is just slighltly higher than the in 2011 when the company made the offering.  Adherex was almost out of business and if it wasn't for Southpoint protecting there investment and agreeing to purchase the follow up shares it might be done now.

 

 

Bullboard Posts